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While coxsackievirus infections have been linked to several autoimmune diseases, very little is known about the
immunogenicity of the coxsackieviruses. Using two genetically related variants of coxsackievirus B4, CB4-P and CB4-V, the
relationship between virulence and antigenicity was examined. The virulent variant, CB4-V, was shown to be more antigenic
than the avirulent CB4-P variant. The increased antigenicity of CB4-V was due to a single amino acid substitution in the VP1
capsid protein (a threonine residue at amino acid position 129), a site that had been previously identified as a major
determinant of viral virulence. Thr-129 of VP1 is predicted to lie within a conformational B cell epitope. In addition, a nearby
linear B cell epitope spanning residues 68 to 82 of VP1 was identified as a potential serotype-specific, neutralization antigenic
site. The linear and conformational B cell epitopes of coxsackievirus B4 may be analogous to antigenic sites 1 and 1B of
poliovirus. To address whether the increased antigenicity of CB4-V influenced the severity of disease, mouse strains that
differ in their outcome to viral infection were analyzed. Mice that developed the most severe disease and succumbed to
infection were more immunoresponsive than mice that survived infection with CB4-V. The data suggest that immune-
mediated mechanisms play a role in the severity of CB4-V induced disease. © 2000 Academic Press
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(INTRODUCTION
Although there is a great deal of information on the
biochemical, biophysical, and genetic characteristics of
the picornaviruses, the mechanisms by which they
cause disease are poorly understood. The group B cox-
sackieviruses, comprising six serotypes (B1 to B6), have
been implicated in a variety of diseases including pan-
creatitis, insulin-dependent diabetes mellitus, myocardi-
tis, myositis, and aseptic meningitis (reviewed in Pal-
lansch, 1997). The broad spectrum of diseases associ-
ated with the group B viruses reflects the existence of
multiple strains, with various degrees of virulence, within
a single serotype. Individual nucleotide substitutions in
noncoding and coding regions of the viral genome de-
termine virulence (reviewed in Chapman et al., 1997).
However, the role of such mutations in virulence is un-
clear. In this report, we examine the relationship be-
tween viral virulence and antigenicity.
For coxsackievirus B4, the RNA genome consists of
7395 nucleotides, and is composed of a 59 untranslated
egion (UTR) of 743 nucleotides, a 39 UTR of 105 nucle-
tides, and an open-reading frame encoding a polypro-
ein of 2183 amino acids which is proteolytically cleaved
Jenkins et al., 1987). Using two closely related variants,
B4-P and CB4-V, we have shown that the development
f mild versus severe disease is dependent on the in-
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86ecting viral strain while the outcome of infection with the
irulent variant is controlled by the host’s genetic back-
round (Ramsingh et al., 1989, 1999). The molecular
eterminants of viral virulence have been identified
Ramsingh and Collins, 1995; Caggana et al., 1993). A
threonine residue at position 129 (thr-129) of VP1 is a
major determinant of virulence while a methionine resi-
due at the same position is attenuating. In addition,
thr-129 of VP1 was shown to affect the recruitment of B
and T cells to the pancreas, the major target organ
(Ramsingh et al., 1997b). The differential recruitment of T
and B cells to the pancreas, by CB4-P and CB4-V, may
reflect altered antigenic sites between the two viral vari-
ants. In this report, we examine the relationship between
virulence and antigenicity and show the following: (i) the
virulent variant, CB4-V, is more antigenic than the aviru-
lent variant, CB4-P, (ii) the increased antigenicity of
CB4-V is due to a single amino acid substitution (thr-129)
in VP1 which is also a major determinant of viral viru-
lence, (iii) thr-129 of VP1 is predicted to lie within a
conformational B cell epitope, and (iv) a nearby B cell
epitope is a potential serotype-specific neutralization an-
tigenic site.
RESULTS
Sequence-structure alignment of coxsackievirus B3
and B4
While the structure of CVB4 has not yet been deter-
mined, the structure of the closely related CVB3 has
been solved (Muckelbauer et al., 1995). The high degree
T87ANTIGENICITY AND VIRULENCE OF CVB4of sequence identity (72%) between the VP1 capsid pro-
teins of B3 and B4 allows a prediction of the structure of
VP1 of CVB4 based on a sequence-structure alignment
with CVB3. A multiple sequence alignment of the VP1
sequences of CVB3, CB4-P, and CB4-V was accom-
plished using PILEUP (Wisconsin Package Version 9.1,
Genetics Computer Group, Madison, Wisconsin) (Fig. 1).
The structural motifs of VP1 of CB4-P and CB4-V were
identified based on the known positions within VP1 of
CVB3. For CVB3 and CVB4, five of the six loops of VP1
are identical in size. The loop that is different in size is
the BC loop which is three residues longer in CVB4.
Three loops (EF, FG, and GH) share a high degree of
sequence identity (78–100%) while the remaining three
loops (BC, DE, and HI) are less conserved (0–38% iden-
tity). We have shown that amino acid 129 of VP1 of CVB4
plays a key role in pathogenesis (Caggana et al., 1993).
FIG. 1. Multiple sequence alignment of the VP1 capsid proteins o
cardiovirulent variant (GenBank, Accession Number M88483) and was
he sequences for CB4-P and CB4-V were from Ramsingh et al. (199
Genetics Computer Group, Madison, Wisconsin). Structural analysis o
in bold. The numbers on the top refer to the CVB3 sequence while the
and dashes indicate gaps.A methionine residue at position 129 of VP1 results in an
attenuated virus while a threonine residue at the sameposition results in a virulent virus. Amino acid 129 of VP1
of CVB4 is predicted to lie within the DE loop.
Antigenicity of CB4-P and CB4-V
To ascertain whether virulence correlates with anti-
genicity, serum samples from mice infected with the
avirulent or the virulent variant of CVB4 were assayed,
for the presence of anti-viral antibodies, by ELISA.
Serum samples were collected from B10.S(12R) mice,
7 days after infection with either CB4-P or CB4-V, and
tested against purified CB4-P and CB4-V. The anti-viral
IgG titers of sera from mice infected with CB4-V (and
tested against CB4-V) were consistently higher than
those of mice infected with CB4-P (and tested against
CB4-P (Fig. 2). When sera from CB4-P-infected mice
were tested against the CB4-V antigen, increased
and CVB4. The CVB3 sequence is the consensus sequence for a
from Lindberg et al. (1987), Klump et al. (1990), and Tracy et al. (1992).
alignment was done using PILEUP (Wisconsin Package Version 9.1,
defined the loops of VP1 (Muckelbauer et al., 1995) which are shown
ers on the bottom refer to the CVB4 sequences. Dots indicate identityf CVB3
derived
2). The
f CVB3
numbbinding of anti-viral IgG was observed (Fig. 3A). Con-
versely, when sera from CB4-V-infected mice were
n
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of IgG was observed (Fig. 3B).
To address the molecular basis of antigenicity of
CVB4, two recombinant chimeric viruses, CB420 and
CB420c (Ramsingh et al., 1997b; Caggana et al., 1993b),
were used. The CB420 construct is genetically identical
to CB4-P except for a point mutation at nucleotide posi-
tion 2833 which results in a threonine residue at position
129 of VP1 (Fig. 4). The CB420c construct is derived from
CB420 but has a methionine residue at position 129 of
VP1. The CB420c construct controls for mutations that
may have occurred at sites other than at nucleotide
position 2833 in the genome of CB420. When sera from
CB4-P- or CB4-V-infected mice were tested against the
CB420 antigen, binding of anti-viral IgG was similar to
FIG. 2. Antigenicity of coxsackievirus B4. Groups of three B10.S(12R)
mice were infected with CB4-P or CB4-V, and serum samples, collected
7 days later, were assayed by ELISA. Uninfected mice served as
controls. Experiments were done at least twice. The data show the
mean and standard deviation of groups of three mice. Sera from
CB4-V-infected mice (F) were tested against the CB4-V antigen. Sera
from CB4-P-infected mice () were tested against the CB4-P antigen.
Sera from uninfected mice were tested against the CB4-V antigen (m )
and the CB4-P antigen ().
FIG. 3. Identification of the molecular determinant of altered antige-
icity of CVB4. Groups of three B10.S(12R) mice were infected with
B4-P, CB4-V, or CB420, and serum samples, collected 7 days later,
ere assayed by ELISA against a panel of antigens. Uninfected mice
erved as controls. Experiments were done at least twice. The data
how the mean and standard deviation of groups of three mice. (A)
era from CB4-P-infected mice were tested against CB4-V (F), CB420
}), CB420c () and no antigen (n ). (B) Sera from CB4-V-infected mice
were tested against CB420 (}), CB4-P (), CB420c (), and no antigen
(n ). (C) Sera from CB420-infected mice were tested against CB4-V (F),
CB420 (}), CB4-P (), CB420c (), and no antigen (n ).that seen with the CB4-V antigen (Figs. 3A and B). When
sera from CB4-P- or CB4-V-infected mice were tested
against the CB420c antigen, binding of anti-viral IgG was
similar to that seen with the CB4-P antigen. Sera from
mice infected with CB420 displayed properties similar to
those observed with samples from CB4-V-infected mice.
Anti-viral IgG titers were higher when assayed against
CB420 and CB4-V and lower when tested against CB4-P
and CB420c (Fig. 3C).
Serum anti-viral titers in different strains of CVB4-
infected mice
Since an antibody response is influenced by the
MHC, various strains of mice can respond differently
to a given antigen. In the studies described above,
B10.S(12R) mice were used. Additional studies fo-
cused on viral antigenicity in two additional strains of
mice with different MHC haplotypes, B10.T(6R) and
Balb/c. The B10.S(12R) (H-2s) and B10.T(6R) (H-2y2)
strains are genetically identical, except within the
MHC. Therefore, any differences in the response to
viral infection, between the two strains, can be attrib-
uted to the MHC. We also examined viral infection in
the commonly used Balb/c strain which has an H-2d
haplotype. Serum samples, harvested from mice in-
fected with either CB4-P or CB4-V, at 7 and 14 days
after infection, were assayed by ELISA using CB4-P
and CB4-V as bound antigen. Serum samples from
uninfected mice served as controls. The antibody titer
was defined as the reciprocal of the serum dilution
that gave an absorbance (at 405 nm) of 1.0 which was
FIG. 4. Genotypes of recombinant chimeric coxsackieviruses. The
top line depicts the structural organization of the coxsackievirus B4
genome (Jenkins et al., 1987). The CB420 recombinant is derived from
DNA clones of CB4-P and CB4-V (Caggana et al., 1993). A BglII-BssHII
fragment of the cDNA of CB4-P was replaced with the corresponding
fragment from the cDNA of CB4-V resulting in a point mutation (T3 C)
at nucleotide position 2833. The CB420c recombinant is derived from
the CB420 recombinant and has a back mutation (C3 T) at nucleotide
osition 2833.20 times above background values. As was observed
for B10.S(12R) mice, the anti-viral IgG titers of sera
o
a , ) an
89ANTIGENICITY AND VIRULENCE OF CVB4from B10.T(6R) and Balb/c mice infected with CB4-V
(and tested against CB4-V) were consistently higher
than those of mice infected with CB4-P (and tested
against CB4-P) (Figs. 5A, B, D, E, G, H). For all three
strains, at 7 days after infection, the anti-viral IgG titers
were 6- to 20-fold higher in CB4-V- than in CB4-P-
infected mice (Table 1). At 14 days after infection,
antibody titers were 2- to 8-fold higher in CB4-V- than
in CB4-P-infected mice. In examining the kinetics of
the antibody response, there was a 2.6 to 11.4-fold
increase in titer, from 1 to 2 weeks after infection, with
CB4-P. The increase in antibody titers for CB4-V-in-
fected mice was less (1.2- to 2.6-fold) than that ob-
served for CB4-P-infected mice and reflects the higher
initial anti-viral IgG titers at 7 days after infection. Of
the three strains of mice, the Balb/c mice had the
lowest anti-viral titers to CB4-P and the B10.T(6R) mice
responded the strongest to viral infection.
When sera from CB4-P-infected mice were tested
against the CB4-V antigen, increased binding of anti-viral
IgG was observed (Figs. 5A, D, G). When sera from
CB4-V-infected mice were tested against the CB4-P an-
FIG. 5. Serum antibody titers of mice infected with coxsackievirus B4.
f three mice were infected with CB4-P, CB4-V, or CB420. Serum sample
nd assayed by ELISA against CB4-P (m , F), CB4-V (h, n ), and CB420 (
dilution that gave an absorbance of 1.0.tigen, decreased binding of anti-viral IgG was observed
(Figs. 5B, E, H). To determine if the increased antigenicity
i
gof CB4-V in B10.T(6R) and Balb/c mice was also due to
thr-129 of VP1, mice were infected with the CB420 con-
struct and serum samples were tested against CB4-P,
CB4-V, and CB420. As with CB4-V-infected mice, the
anti-viral IgG titers of mice infected with CB420 were
higher against CB420 and CB4-V and lower against
CB4-P (Figs. 5C, F, I).
h of the three mouse strains, B10.S(12R), B10.T(6R), and Balb/c, groups
collected 7 (open symbols) and 14 days (closed symbols) after infection
tigens. Serum antibody titer was defined as the reciprocal of the serum
TABLE 1
Summary of Anti-Viral IgG Titers from Mice Infected
with CB4-P or CB4-V
Mouse strain Virus
Anti-viral IgG titera
7 days p.i. 14 days p.i.
B10.S(12R) CB4-P 873 9,912
B10.S(12R) CB4-V 17,920 21,651
B10.T(6R) CB4-P 2,336 16,384
B10.T(6R) CB4-V 14,336 37,952
Balb/c CB4-P 1,210 3,090
Balb/c CB4-V 11,720 24,950
a Represents the mean titer of groups of three mice. Each group ofFor eac
s werenfected mice was assayed in duplicate against the homologous anti-
en and then retested. Each value represents the mean of 12 assays.
oi
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To determine if thr-129 of VP1 lies within a linear B cell
epitope, a panel of overlapping peptides (15-mer) span-
ning residues 48 to 150 (Table 2) was synthesized.
Across this region, the sequences of CB4-P and CB4-V
are identical except for amino acid 129. Two peptides,
spanning residues 126 to 140 and containing met-129
(peptide 9) or thr-129 (peptide 9v), were synthesized.
Serum samples from B10.S(12R) mice, 7 days after infec-
tion with either CB4-P or CB4-V, were assayed, by ELISA,
against the panel of synthetic peptides (Fig. 6). Sera from
CB4-P- and CB4-V-infected mice bound strongly to pep-
tide 3 (residues 68–82) and weakly to peptide 7 (residues
106–120). Serum samples did not bind to peptides 9 or 9v
(residues 126–140). To determine if peptides 3 and 7
were immunodominant B cell epitopes, sera from addi-
tional strains of infected mice, B10.T(6R) and Balb/c mice,
were tested. Sera from infected B10.T(6R) and Balb/c
mice also bound strongly to peptide 3 and weakly to
peptide 7.
Serum-neutralizing activity can be inhibited by a VP1
peptide
The next question that was addressed was whether
the B cell epitopes (peptides 3, 7) contained a neutral-
ization antigenic site. To identify neutralization antigenic
sites, the panel of peptides was tested in an inhibition
assay. Initial studies focused on the peptide(s) that could
inhibit the neutralizing activity of sera from B10.S(12R)
mice that had been infected with either CB4-P or CB4-V.
Peptide 3 consistently inhibited the neutralizing activity
of sera from B10.S(12R) mice (Table 3). To determine if
peptide 3 was an immunodominant neutralization anti-
TABLE 2
Synthetic Peptides of CVB4 Spanning the Predicted BC
and DE Loops of VP1
Peptide
Amino acid
position Sequencea
1 48–62 MQTRHVHNYHSRSES
2 58–72 SRSESSIENFLCRSA
3 68–82 LCRSACVIYIKYSSA
4 78–92 KYSSAESNNLKRYAE
5 88–102 KRYAEWVINTRQVAQ
6 96–110 NTRQVAQLRRKMEMF
7 106–120 KMEMFTYIRCDMELT
8 116–130 DMELTFVITSHQEMS
9 126–140 HQEMSTATNSDVPVQ
9v 126–140 HQETSTATNSDVPVQ
10 136–150 DVPVQTHQIMYVPPG
a BC-loop sequence is in bold; DE-loop sequence is in bold and
talics.genic site, sera from additional strains of mice, B10.T(6R)
and Balb/c, were tested. Again, peptide 3 was able toinhibit the neutralizing activity of sera from different
strains of mice, infected with either CB4-P or CB4-V. To
determine if peptide 3 contained a potential serotype-
specific neutralization antigenic site, subsequent exper-
iments focused on whether peptide 3 could inhibit the
neutralizing activity of sera from mice infected with
CVB3/0. Peptide 3 did not inhibit the neutralizing activity
of sera from CVB3-infected mice (Table 3).
DISCUSSION
While the B and T cell epitopes of polioviruses have
been characterized in great detail (reviewed in Minor,
1990), very little is known about the immunogenicity of
the coxsackieviruses which have been implicated in a
variety of autoimmune diseases (reviewed in Ramsingh
FIG. 6. Linear B cell epitopes of VP1 of coxsackievirus B4 defined by
synthetic peptides. For each of the three mouse strains, B10.S(12R),
B10.T(6R), and Balb/c, groups of three mice were infected with CB4-P
(open symbols) or CB4-V (closed symbols). Uninfected mice served as
controls. Serum samples were collected 7 days later and assayed by
ELISA against a panel of synthetic peptides of VP1. Absorbance 5
ptical density (405 nm) of serum from infected mouse 2 optical
density (405 nm) of serum from uninfected mouse. Experiments were
done at least twice and representative results are shown.
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91ANTIGENICITY AND VIRULENCE OF CVB4et al., 1997a). In this report, we examined the relationship
between viral virulence and antigenicity and show that
the virulent phenotype correlates with increased antige-
nicity.
We have previously shown that the avirulent and viru-
lent variants differ in their growth rates both in vitro
(Ramsingh et al., 1995) and in vivo (Ramsingh et al.,
1997b). The virulent variant, CB4-V, grows more efficiently
than the avirulent variant, CB4-P. The argument may be
made that differences in antigenicity between the two
variants may simply be due to differences in growth
rates. However, a recombinant virus CB420, that has a
low growth rate in vitro (Ramsingh et al., 1995) and an
ntermediate growth rate (lower than CB4-V but higher
han CB4-P) in vivo (unpublished data) was shown to be
s antigenic as the CB4-V variant. The molecular basis of
ltered antigenicity is a single amino acid substitution at
osition 129 of the VP1 capsid protein which is also a
ajor determinant of viral virulence (Caggana et al.,
993). A threonine residue at position 129 (thr-129), pre-
icted to lie within the DE loop of VP1, results in in-
reased antigenicity. Thr-129 of VP1 is expected to be
ithin a conformational B cell epitope since it is not
ithin a linear epitope.
In addition to the conformational B cell epitope, we
ave also identified a nearby linear B cell epitope, within
peptide (3) spanning residues 68 to 82 of VP1, that is
lso a neutralization antigenic site. Peptide 3 cannot
nhibit the neutralizing activity of sera from CVB3- in-
ected mice, suggesting that peptide 3 may contain a
erotype-specific neutralization antigenic site. Additional
tudies with the remaining four serotypes (B1, B2, B5,
nd B6) are necessary to confirm the serotype specificity
f peptide 3. But, if true, then one would expect to
bserve sequence differences within the corresponding
egion of the six serotypes of the group B coxsackievi-
uses. A multiple sequence alignment of amino acid
esidues 68 to 82 of VP1 of all six serotypes is shown in
T
Serum-Neutralizing Activity
Virus Mouse strain
Inhibiti
1 2 3
B4-P B10.S(12R) 0 0 100
B10.T(6R) 0 0 100
Balb/c 0 0 100
B4-V B10.S(12R) 0 0 100
B10.T(6R) 0 0 100
Balb/c 0 0 100
VB3 B10.S(12R) ND ND 0
Note. Serum samples from groups of six to eight mice were analyze
4–32. ND, not done.ig. 7. As predicted, each serotype has a unique se-
uence. Sequence differences cluster in two regions.egion 1 contains amino acid residues 75 to 78 and is
ocated within beta-strand B while region II contains
esidues 80 to 82 and is located at the C-terminus of
eta-strand B and the N-terminus of the BC loop. Peptide
shares a five amino acid overlap with peptide 3 but did
ot inhibit the neutralizing activity of sera from CVB4-
nfected mice. The data suggest that the serotype spec-
ficity of the neutralization antigenic site, within peptide 3,
ust be due to region I alone or to a combination of
egions I and II. Based on the structural data for CVB3
Muckelbauer et al., 1995), all but one amino acid within
egions I and II are surface residues and, therefore,
eadily accessible for binding to antibodies. Using a
VB3/4 chimera, Reimann et al. (1991) identified an ad-
acent site (amino acids 83–87) within the BC loop of VP1
f CVB4 as a serotype-specific neutralizing antigenic site
n rabbits. The BC loop of VP1 and flanking sequence
ithin beta-strand B contain linear B cell epitopes that
re neutralizing antigenic sites in both rabbits and mice.
he B cell epitopes for rabbits and mice are adjacent and
ot colinear, suggesting differences in antigen process-
ng between species.
Since an antibody response is influenced by the MHC
Inhibited by a VP1 Peptide
onolayer formation (% wells) VP1 peptides
5 6 7 8 9/9v 10
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
ND ND ND ND ND ND
rately in quadruplicate. Total number of wells analyzed per group was
FIG. 7. Multiple sequence alignment of a serotype-specific neutral-
ization antigenic site within VP1 of the group B coxsackieviruses. The
structural motifs, a-Z, b-B, and BC loop of VP1, are based on the
structure of CVB3 (Muckelbauer et al., 1995). Two regions of noncon-
served sequence, I and II, are outlined. All but one (denoted by an
asterisk) of the nonconserved amino acid residues are surface resi-
dues. Sequence data were obtained from Ramsingh et al. (1992)
(CVB4), Chapman et al. (1994) (CVB3), Iizuka et al. (1997) (CVB1),ABLE 3
Can Be
on of m
4
0
0
0
0
0
0
NDPolacek et al. (1999) (CVB2), Zhang et al. (1993) (CVB5), and Oberste et
al. (1999) (CVB6).
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92 HALIM AND RAMSINGHand its subsequent interactions with the T cell receptor,
in addition to variation among species, strain variation
within a species can also exist. Different strains can
recognize distinct epitopes within a given antigen. For
complex protein antigens, the immune response is often
limited to a small number of epitopes. In this study, we
identified the viral sequences that could elicit B cell
responses in three strains of mice with different MHC
haplotypes, H-2s, H-2y2 and H-2d. In all three strains of
ice, the CB4-V variant was more antigenic than the
B4-P variant, the increased antigenicity was due to
hr-129 of VP1 which is predicted to be within a confor-
ational B cell epitope, and the linear B cell epitope
panning residues 68 to 82 of VP1 was a neutralization
ntigenic site. Since the three strains of mice responded
o both the conformational and the linear B cell epitopes
f VP1, these two epitopes can be considered immuno-
ominant in mice.
The B cell epitopes of polioviruses have been identi-
ied based on studies of mutant viruses that are resistant
o neutralization by monoclonal antibodies (reviewed in
inor, 1990). Five neutralization antigenic sites have
een identified for poliovirus type 1. Four sites (1B, 2, 3A,
B) contain noncontiguous sequences and represent
onformational B cell epitopes. Site 1 consists of a se-
uential epitope that includes amino acid residues 97 to
01 of VP1 which is within the BC loop. Two sites, 2 and
B, contain sequences from different capsid proteins
hile sites 1B and 3A contain sequences within a single
apsid protein. In a multiple sequence alignment be-
ween CVB4 and poliovirus (Ramsingh et al., 1992), the
equential epitope spanning residues 68 to 82 (peptide
) of VP1 of CVB4 corresponds to residues 81 to 97 of
P1 of poliovirus which is adjacent to neutralization
ntigenic site 1 (residues 97–101). The sequential nature,
ocation, and immunodominance of the B cell epitope of
VB4 suggest that peptide 3 may correspond to neutral-
zation antigenic site 1 of poliovirus type 1 (Fig. 8). We
ave also identified the DE loop of VP1 of CVB4 as part
f a conformational epitope. For poliovirus type 1, the DE
oop of VP1 and the linear neutralization antigenic site 1
ompose a conformational epitope, site 1B (Wiegers et
l., 1989). A similar epitope was also identified in human
hinovirus 14 (Sherry et al., 1986). By analogy with polio-
irus and rhinovirus, the DE loop of VP1 and the newly
dentified site 1 of CVB4 may constitute neutralization
ntigenic site 1B (Fig. 8). When the neutralization anti-
enic site contains met-129 of VP1, antibody titers were
ow when tested against the CB4-P antigen and high
hen tested against the CB4-V and CB420 antigens. The
ata suggest that the anti-viral IgG against the confor-
ational epitope containing met-129 of VP1 has a
reater affinity for the epitope when a threonine residue
eplaces the methionine residue. When the neutraliza-
ion antigenic site contains thr-129 of VP1, the anti-viral
C
pgG response is primarily against the conformational
pitope and is rapid and strong.
Is the correlation between viral virulence and in-
reased antigenicity fortuitous or does antigenicity influ-
nce disease severity? Since the outcome of infection
ith the virulent variant, CB4-V, is influenced by several
actors including the genetic background of the host
Ramsingh et al., 1989, 1999), a comparison of antibody
esponses will be restricted to the B10 mice. Of the two
10 strains, the B10.S(12R) mice survive infection while
he B10.T(6R) mice succumb to infection with CB4-V
Ramsingh et al., 1989). If antigenicity influences disease
everity then one would expect to see a difference in the
nti-viral antibody response in the B10 strains of mice.
verall, the B10.T(6R) mice are more immunoresponsive
han the B10.S(12R) mice to viral infection (CB4-V, CB4-P).
ur working model is that viral virulence is due to in-
reased antigenicity which in a more immunoresponsive
ost leads to a more severe disease. If true, then one
ould expect that immunopathological mechanisms play
role in CB4-V-induced disease. We have recently
hown that T cells contribute to the severity of CB4-V-
nduced disease (Ramsingh et al., 1999). Ongoing stud-
es focus on the immune-mediated mechanisms that
xacerbate disease subsequent to viral infection.
MATERIALS AND METHODS
ells and viruses
The passage histories of the two viruses, CB4-P and
B4-V, have been described previously (Ramsingh et al.,
989). A noncardiovirulent CVB3, CVB3/0, was obtained
rom Dr. Steven Tracy (University of Nebraska Medical
FIG. 8. A model of the antigenic structure of VP1 of coxsackievirus
B4. The linear neutralization antigenic site 1 is expected to be within
the sequence spanning residues 75 to 82 of VP1. Neutralization anti-
genic site 1B is predicted to contain site 1 and sequences from the DE
loop including amino acid residue 129.enter, Omaha) and grown in HeLa cells. After plaque
urification, large-scale stocks of CB4-P and CB4-V were
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93ANTIGENICITY AND VIRULENCE OF CVB4prepared in HeLa cells and LLC-MK2(D) cells, respec-
tively. Viral infectivity was determined by plaque assay
with LLC-MK2(D) cells. The construction of the two re-
combinant viruses, CB420 and CB420c, has been re-
ported (Ramsingh et al., 1997b; Caggana et al., 1993b).
he CB420 construct is genetically identical to the CB4-P
ariant except for a point mutation (U 3 C) at position
833. The phenotype of CB420 is similar to that of CB4-V
Ramsingh et al., 1997b; Caggana et al., 1993b). The
B420c construct is derived from CB420 but with a back
utation (C3 U) at position 2833. The CB420c construct
ontrols for mutations that may have occurred at sites
ther than at nucleotide position 2833 in the genome of
B420. The phenotype of CB420c is similar to that of
B4-P (Ramsingh et al., 1997b).
Virus was purified as described by Minor (1985).
riefly, infected cells were lysed by repeated freezing
nd thawing and clarified by low-speed centrifugation.
irus was concentrated by precipitation with polyethyl-
ne glycol and sodium chloride, layered onto linear gra-
ients of sucrose from 15 to 45%, and centrifuged at
0,000 g for 4 h at 4°C. Virus was collected, diluted in
PBS supplemented with 2% BSA, and further purified by
ultracentrifugation at 100,000 g for 1 h at 4°C. Purified
irus was resuspended in PBS, filter sterilized, and
tored at 280°C.
nfection of mice
In our model of CVB4-induced pancreatic disease, the
utcome of infection depends on the genotype of the
irus and on several host factors including genetic back-
round and major histocompatability complex (MHC)
Ramsingh et al., 1989). For these studies, two H-2 con-
enic strains, B10.S(12R) (H-2s) and B10.T(6R) (H-2y2), and
Balb/c substrain, Balb/cByJ (H-2d) were used. The B10
ice are maintained in our animal facility. The Balb/c
ice are bred in the Wadsworth Center’s Animal Core
acility. Four- to six-week-old mice were injected intra-
eritoneally with 104 PFU of virus diluted in phosphate-
uffered saline. Control mice were injected with phos-
hate-buffered saline. Infection with CB4-V, but not
B4-P, is associated with morbidity. We have shown that
xocrine pancreatic insufficiency contributes to morbid-
ty and mortality during CB4-V infection (Ramsingh et al.,
999). To minimize morbidity, CB4-V-infected mice were
iven supplements of pancreatic enzymes (pancreatin, 1
g/ml) and glucose (30%) in their drinking water which
as changed daily. Pancreatin and/or glucose supple-
ents given to CB4-P-infected mice had no effect on viral
eplication or antibody titers. Mice were bled from the tail
ein at 7 and 14 days after infection and serum samples
ere assayed by ELISA. All animal procedures were
pproved by the Institutional Animal Care and Use Com-
ittee of the Wadsworth Center.
ietection of anti-coxsackievirus antibodies by ELISA
Anti-viral antibodies were detected, by an adaptation
f an indirect ELISA (Coligan et al., 1996), using either
urified virus or viral peptides as bound antigen in 96-
ell round-bottom plates (Costar). Plates were coated
ith 0.25 mg of purified virus in PBS (10 mM Na2HPO4, 2
mM NaH2PO4, 150 mM NaCl), at 4°C overnight, or with
.0 mg of peptide in 50 mM sodium phosphate buffer, pH
6.6, 0.2 M NaCl, 0.2% BSA, at room temperature over-
night. Plates were washed three times in PBS/0.01%
Tween 20 (for virus antigen) or in PBS supplemented with
0.5 M NaCl and 0.02% Tween 20 (for peptide antigen) and
blocked with PBS/20% fetal calf serum for 1 h at 37°C.
Serial fourfold dilutions of sera, in PBS/2% fetal calf
serum (for virus antigen) or PBS/0.2 M NaCl/0.05%
Tween 20 (for peptide antigen), were added beginning at
a dilution of 1:320. After an incubation at 37°C for 30 min,
plates were washed three times and incubated with a
horseradish peroxidase-conjugated goat anti-mouse IgG
(Southern Biotechnology Associates, Inc., Birmingham,
AL) for 30 min at 37°C. After washing, the enzymatic
reaction was developed with a substrate solution, ABTS
(2,29-azino-bis-(3-benzthiazoline-6-sulfonic acid) solu-
tion) (Southern Biotechnology Associates, Inc.) for 45 min
at room temperature. The optical density was measured
with an ELISA plate reader (Thermomax, Molecular De-
vices) at 405 nm. Serum samples were tested in dupli-
cate. Sera from uninfected mice served as controls.
Serum neutralization-inhibition assay
Prior to the development of a neutralization-inhibition
assay, the conditions for a serum neutralization assay
were determined. Serum samples, from infected mice,
were diluted (1/100 to 1/1000) in PBS and incubated with
varying amounts (102 to 104 PFU) of the corresponding
irus for 90 min at room temperature. The serum/virus
ixture was then added to a suspension of LLC-MK2(D)
ells in Costar 24-well plates (4 3 104 cells/well). Sam-
les were assayed in quadruplicate. After incubation at
7°C for 2 days, wells were scored for monolayer forma-
ion. For sera from CVB4- or CVB3-infected mice, a dilu-
ion of 1/100 completely neutralized 104 PFU of the cor-
responding virus resulting in the formation of a mono-
layer in 100% of the wells. As expected, sera from CB4-
P-infected mice neutralized both CB4-P and CB4-V but
not CVB3/0. Sera from CVB3/0-infected mice neutralized
CVB3/0 but not CB4-P and CB4-V.
For the neutralization-inhibition assay, 20 mg of pep-
ide was incubated with serum, diluted 1/100 in PBS, for
0 min at room temperature. The serum/peptide mix was
hen incubated with 104 PFU of the appropriate virus for
0 min at room temperature. The serum/peptide/virus
ixture was added to a suspension of LLC-MK2(D) cells
4n Costar 24-well plates (4 3 10 cells/well). Samples
were assayed in quadruplicate. After incubation at 37°
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94 HALIM AND RAMSINGHfor 2 days, wells were scored for inhibition of mono-
layer formation. Controls included the following combi-
nations (a) peptide and cell suspension (formation of a
monolayer); (b) virus and cell suspension (inhibition of
monolayer formation); (c) peptide, virus, and cell suspen-
sion (inhibition of monolayer formation); (d) peptide, se-
rum, and cell suspension (formation of a monolayer); and
(e) serum, non-viral peptide, virus, and cell suspension
(formation of a monolayer).
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